MIM
HRTX icon

MetLife Investment Management’s Heron Therapeutics HRTX Stock Holding History

MetLife Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-87,754
Closed -$114K – 2806
2025
Q4 		$114K Sell
87,754
-4,672
-5% -$5.77K ﹤0.01% 2548
2025
Q3 		$116K Hold
92,426
– – ﹤0.01% 2583
2025
Q2 		$191K Buy
92,426
+37,738
+69% +$77.1K ﹤0.01% 2222
2025
Q1 		$120K Sell
54,688
-18,002
-25% -$34.9K ﹤0.01% 2443
2024
Q4 		$111K Buy
72,690
+635
+0.9% +$1.03K ﹤0.01% 2570
2024
Q3 		$143K Hold
72,055
– – ﹤0.01% 2459
2024
Q2 		$252K Buy
72,055
+31,944
+80% +$98.1K ﹤0.01% 2104
2024
Q1 		$111K Sell
40,111
-13,453
-25% -$33.8K ﹤0.01% 2483
2023
Q4 		$91.1K Hold
53,564
– – ﹤0.01% 2645
2023
Q3 		$55.2K Hold
53,564
– – ﹤0.01% 2816
2023
Q2 		$62.1K Hold
53,564
– – ﹤0.01% 2878
2023
Q1 		$80.9K Hold
53,564
– – ﹤0.01% 2634
2022
Q4 		$134K Hold
53,564
– – ﹤0.01% 2470
2022
Q3 		$226K Hold
53,564
– – ﹤0.01% 2217
2022
Q2 		$149K Hold
53,564
– – ﹤0.01% 2498
2022
Q1 		$306K Buy
53,564
+20,791
+63% +$152K ﹤0.01% 2079
2021
Q4 		$299K Hold
32,773
– – ﹤0.01% 1818
2021
Q3 		$350K Hold
32,773
– – ﹤0.01% 1737
2021
Q2 		$509K Hold
32,773
– – ﹤0.01% 1557
2021
Q1 		$531K Sell
32,773
-6,301
-16% -$112K ﹤0.01% 1492
2020
Q4 		$827K Hold
39,074
– – 0.01% 1218
2020
Q3 		$579K Hold
39,074
– – 0.01% 1297
2020
Q2 		$575K Buy
39,074
+2,530
+7% +$41.6K 0.01% 1303
2020
Q1 		$429K Hold
36,544
– – 0.01% 1294
2019
Q4 		$859K Buy
36,544
+2,703
+8% +$59.8K 0.01% 1167
2019
Q3 		$626K Hold
33,841
– – 0.01% 1300
2019
Q2 		$629K Buy
33,841
+4,475
+15% +$89.4K 0.01% 1347
2019
Q1 		$718K Hold
29,366
– – 0.01% 1234
2018
Q4 		$762K Hold
29,366
– – 0.01% 1133
2018
Q3 		$929K Hold
29,366
– – 0.01% 1166
2018
Q2 		$1.14M Buy
29,366
+4,394
+18% +$140K 0.01% 969
2018
Q1 		$689K Buy
24,972
+2,926
+13% +$66.4K 0.01% 1177
2017
Q4 		$399K Buy
+22,046
New +$359K ﹤0.01% 1531

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

MetLife Investment Management's HRTX Position: Q1 2026 in Review

MetLife Investment Management sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 87,754 shares — an estimated $114K sold.

MetLife Investment Management first reported a position in HRTX in Q4 2017 and held it in 33 quarters. The position peaked at $1.14M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • MetLife Investment Management reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • MetLife Investment Management sold 87,754 Heron Therapeutics shares in Q1 2026, an estimated $114K.
  • MetLife Investment Management first reported a position in Heron Therapeutics in Q4 2017 and held it in 33 quarters.
  • MetLife Investment Management's Heron Therapeutics position peaked at $1.14M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.